Anemia in patients on combined androgen block therapy for prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 383-384, 2004.
Article
Dans Anglais
| WPRIM
| ID: wpr-270880
ABSTRACT
<p><b>AIM</b>To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer.</p><p><b>METHODS</b>One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy.</p><p><b>RESULTS</b>The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05).</p><p><b>CONCLUSION</b>Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de la prostate
/
Thérapeutique
/
Hémoglobines
/
Orchidectomie
/
Adénocarcinome
/
Association thérapeutique
/
Antinéoplasiques hormonaux
/
Protéines sécrétoires de la prostate
/
Utilisations thérapeutiques
/
Traitement médicamenteux
Limites du sujet:
Adulte
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Asian Journal of Andrology
Année:
2004
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS